Blog
About

  • Record: found
  • Abstract: found
  • Article: not found

Understanding clinical development of chimeric antigen receptor T cell therapies.

Read this article at

ScienceOpenPublisherPubMed
Bookmark
      There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

      Abstract

      In the past decade, many clinical trials with gene- and cell-based therapies (GCTs) have been performed. Increased interest in the development of these drug products by various stakeholders has become apparent. Despite this growth in clinical studies, the number of therapies receiving marketing authorization approval (MAA) is lagging behind. To enhance the success rate of GCT development, it is essential to better understand the clinical development of these products. Chimeric antigen receptor (CAR) T cells are a GCT product subtype with promising efficacy in cancer treatment which are tested in many clinical trials, but have not yet received MAA.

      Related collections

      Author and article information

      Affiliations
      [1 ] Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
      [2 ] Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands. Electronic address: p.meij@lumc.nl.
      Journal
      Cytotherapy
      Cytotherapy
      Elsevier BV
      1477-2566
      1465-3249
      Jun 2017
      : 19
      : 6
      28433515
      S1465-3249(17)30524-8
      10.1016/j.jcyt.2017.03.070

      Comments

      Comment on this article